English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Image-guided adaptive brachytherapy (IGABT) using magnetic resonance imaging (MRI) has been accepted as a novel treatment technique for cervical cancer. During the development of MRI-based IGABT, a very important concept called “High-risk clinical target volume (HR-CTV)” was introduced. However, computed tomography (CT)-based IGABT is the most common modality in Japan. MRI-based IGABT was initiated in September 2014 at Kobe University Hospital and 50 patients were treated through March 2016. Although a total HR-CTV D90 ranging from 80 to 85 Gy equivalent dose in 2 Gy fractions in combination with 45 Gy of external beam radiotherapy (EBRT) and 7 Gy×4 fractions of IGABT is the most standard treatment aim in European institutions, our aim for a total HR-CTV D90 was a 70–80 Gy because of the use of the central shielding technique for the protection of organs at risk in the late phase of EBRT. The mean total HR-CTV D90 for our 50 patients was 77 Gy. Although our aim was achieved, it was relatively low because Japanese radiotherapy protocols for cervical cancer still differ from those in European institutions. Therefore, a new treatment protocol, which is closer to the global standard, should be established.

Image‐Guided Adaptive Brachytherapy for Cervical Cancer Using Magnetic Resonance Imaging: Overview and Experience